Carbon Suspension vs. Metallic Marker for Axillary Lymph Node Marking in Breast Cancer After Neoadjuvant Therapy
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
This single-center, randomized study aims to compare the intraoperative detection rates of axillary lymph nodes marked with carbon suspension versus metallic markers in breast cancer patients (T1-3N1M0) before neoadjuvant therapy. Primary endpoint: frequency of marked lymph node identification during surgery. Secondary endpoints: time from marking to surgery and quality of life (EORTC QLQ-BR23).
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Kobiety od 18 lat
- •Potwierdzony rak piersi w stadium T1-3N1M0
- •Dobry stan sprawności (ECOG 0-1)
- •Wskazanie do leczenia neoadjuwantowego
- •Podpisana świadoma zgoda
✗ Disqualifies
- •Brak zmniejszenia zajętych węzłów chłonnych po leczeniu neoadjuwantowym
- •Progresja choroby z przerzutami odległymi
- •Poważne choroby współistniejące (serca, płuc, wątroby)
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- August 6, 2025
- Sex
- Female only
Therapies / drugs in trial
Locations (1)
St. Petersburg State University
Saint Petersburg, Russia
Trial contact
Alina A Olchonova, Physician
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 7/1/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.